GÖRG advises Merck KGaA on the sale of a research facility to Nuvisan Pharma Grafing GmbH
[Frankfurt am Main, ] GÖRG advised the leading healthcare and life sciences business Merck KGaA (Darmstadt) on its sale of a pre-clinical research facility in Grafing near Munich to Nuvisan Pharma Grafing GmbH, a business of the Nuvisan group. The undertaking sold is a specialised facility in the area of drug metabolism and pharmacokinetics. In total, about 40 staff members are employed by the facility. The transaction was structured as a sale of assets.
The facility undertakes highly-specialised research and testing of drugs at the pre-clinical stage. Merck KGaA has ensured that the expertise of the facility will remain available to it in future by entering into a long-term partnership.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.
The GÖRG team advising on the sale consisted of experts in the areas of corporate/M&A, healthcare and regulatory law, labour law and real estate law.
Rose Brounts, in-house counsel, Group Legal & Compliance
Advisors to Merck KGaA
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Michael Heise LL.M. (University of Pennsylvania), Associated Partner, Corporate/M&A, Frankfurt am Main (transaction lead)
Dr. Lars Nevian, Partner, Labour, Frankfurt am Main
Christopher J. Wright, J.D., LL.M., Counsel, Corporate/M&A, Berlin
Dr. Ulrich Jacob, Counsel, Real Estate, Frankfurt am Main
Dr. Marc Schüffner, Associated Partner, Healthcare/Regulatory, Berlin
Dr. Heiko Reiter, Associate, Labour, Frankfurt am Main
Advisors to Nuvisan Pharma Grafing GmbH
TRACC Legal Rechtsanwälte GbR (Munich)
Dr. Thomas Lotz, Corporate/M&A, Munich
Dr. Thorsten Steinhaus, Corporate/M&A, Munich